Two people infected with the same strain of COVID-19 can have vastly different experiences. One might never even sniffle, and ...

The market dynamics for Epstein-Barr virus (EBV) are evolving, driven by the high prevalence of infection worldwide, the growing recognition of EBV-associated malignancies and other complications, and ...

The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support ...

Sacramento-area resident Lisa Ferrero, was only given 5 years to live before she participated in a clinical trial exploring ...

New office and laboratory at CIC Philadelphia will support US biopharma companies, CDMOs, and research institutions ...

The potentially registrational Phase 2 study will evaluate CLN-049 in patients with relapsed or refractory AML who have received up to two prior lines of therapy. Following a dose-optimization phase ...

Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

Vir Biotechnology, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the ...

A Nature Reviews Cancer review argues that metabolism, from CAR design and manufacturing conditions to the patient's diet, is ...

Matchpoint Therapeutics raised $150 million in Series B funding to advance MPT-062 toward clinical proof of concept. Explore the investors and pipeline.